TABLE 1.
Baseline demographic characteristics of the ADNI-1, -GO, −2 cohorts
| Characteristic | N | Overall group (N = 1545) | CN (n = 364) | SMC (n = 98) | EMCI (n = 282) | LMCI (n = 497) | AD (n = 304) | P-value |
|---|---|---|---|---|---|---|---|---|
| Age years (SD) | 1545 | 73.67 (7.2) | 74.63 (5.7) | 72.24 (5.6) | 71.14 (7.5) | 74.09 (7.5) | 74.65 (7.8) | <0.001 |
| Male, % (#) | 1545 | 54 (840) | 48 (176) | 42 (41) | 55 (154) | 61 (304) | 54 (165) | <0.001 |
| Education years (SD) | 1545 | 15.91 (2.8) | 16.30 (2.77) | 16.73 (2.5) | 15.98 (2.6) | 15.86 (2.9) | 15.20 (3.0) | <0.001 |
| APOE4 +, % (#) | 1545 | 47 (726) | 28 (103) | 33 (32) | 43 (120) | 54 (270) | 66 (201) | <0.001 |
| ADAS-Cog13, (SD) | 1534 | 16.82 (9.6) | 9.18 (4.3) | 8.82 (4.0) | 12.57 (5.3) | 18.70 (6.6) | 29.74 (8.1) | <0.001 |
| MMSE (SD) | 1545 | 27.17 (2.6) | 29.08 (1.1) | 29.00 (1.2) | 28.33 (1.5) | 27.16 (1.8) | 23.23 (2.0) | <0.001 |
| CSF T-tau (SD) | 1111 | 90.10 (53.5) | 68.71 (22.3) | 64.91 (31.3) | 75.82 (47.3) | 101.18 (55.8) | 125.77 (59.9) | <0.001 |
| CSF Abeta1–42 (SD) | 1127 | 174.50 (53.8) | 200.72 (51.6) | 202.06 (48.5) | 184.05 (50.9) | 162.8 (51.4) | 139.91 (39.5) | <0.001 |
| T-tau/Abeta1–42 | 1111 | 0.62 (0.50) | 0.39 (0.27) | 0.35 (0.23) | 0.39 (0.47) | 0.72 (0.52) | 0.97 (0.54) | <0.001 |
| Log T-tau/Abeta1–42 (SD) | 1111 | −0.33 (0.33) | −0.49 (0.25) | −0.52 (0.24) | −0.43 (0.32) | −0.25 (0.32) | −0.08 (0.26) | <0.001 |
Abbreviations: ADAS-Cog13, Alzheimer’s Disease Assessment Scale, 13-item cognitive subscale; APOE, apolipoprotein ε4; ADNI, Alzheimer’s Disease Network Initiative; CN, cognitively normal; CSF, cerebrospinal fluid; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SD, standard deviation